2024年12月31日,国家药品监督管理局的药品通知件送达信息显示,九源基因旗下司美格鲁肽注射液在列。这意味着该产品上市申请暂未获批准。受此消息影响,1月2日,刚于2024年11月上市的九源基因港股开盘即跌,最终报收6.26港元,跌5.15%。首个国产司美格鲁肽暂未获批司美格鲁肽是一款GLP-1受体激动剂,原研药厂商为丹麦制药企业诺和诺德。2023年,马斯克在社交平台上发布自己使用司美格鲁肽减重...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.